Balyasny Asset Management
KRYS icon

Balyasny Asset Management’s Krystal Biotech KRYS Stock Holding History

Balyasny Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-40,000
Closed -$7.28M – 3020
2024
Q3 		$7.28M Buy
40,000
+25,000
+167% +$4.82M 0.01% 1093
2024
Q2 		$2.75M Buy
+15,000
New +$2.52M ﹤0.01% 1422

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balyasny Asset Management's KRYS Position: Q3 2024 in Review

Balyasny Asset Management sold out of Krystal Biotech (KRYS) in Q3 2024, closing a stake of 59,810 shares — an estimated $11.5M sold.

Balyasny Asset Management first reported a position in KRYS in Q4 2022 and held it in 7 quarters. The position peaked at $31.8M in Q4 2023. 283 funds tracked by Wall St. Rank hold KRYS as of Q3 2024.

  • Balyasny Asset Management reported no remaining Krystal Biotech position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 59,810 Krystal Biotech shares in Q3 2024, an estimated $11.5M.
  • Balyasny Asset Management first reported a position in Krystal Biotech in Q4 2022 and held it in 7 quarters.
  • Balyasny Asset Management's Krystal Biotech position peaked at $31.8M in Q4 2023.
  • 283 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.